Anlon Healthcare to Acquire 67.48% Stake in Apiqo Organics for Rs. 5,40,06,960

Anlon Healthcare Limited has entered into a Share Purchase Agreement (SPA) with Apiqo Organics Private Limited (formerly known as M/s Apple Life Science, a partnership firm) for the acquisition of 67.48% shareholding. The Target Company is an Indian private limited company, incorporated on December 1, 2025, and is engaged in manufacturing pharmaceutical intermediate, industrial and fine chemicals and inorganic chemicals. The acquisition will enhance Anlon’s vertical integration, secure critical supply of high-quality intermediates, increase annual manufacturing capacity for advanced pharmaceutical intermediates, and strengthen its ability to deliver reliable, cost-effective solutions to global pharmaceutical partners. The consideration for the acquisition is Rs. 5,40,06,960, which will be paid in cash. The acquisition is expected to be completed within 3 months from the date of signing of the SPA.